Study on Axatilimab and Corticosteroids for Initial Treatment of Chronic Graft-Versus-Host Disease in Patients

3 1 1

What is this study about?

This clinical trial is focused on studying a condition known as chronic graft-versus-host disease (cGVHD). This is a complication that can occur after a stem cell or bone marrow transplant, where the donated cells attack the recipient’s body. The study will explore the effectiveness of a new treatment involving a medication called Axatilimab (INCA034176), used in combination with corticosteroids, which are a type of steroid medication. The trial will also include a comparison with a placebo to evaluate the treatment’s effectiveness.

The purpose of the study is to compare how well Axatilimab works in combination with corticosteroids compared to a placebo in treating moderate or severe cases of cGVHD. Participants in the study will receive either the new treatment or a placebo, and their progress will be monitored over time. The study will involve regular check-ups and assessments to track the condition and any changes in symptoms.

Participants will be randomly assigned to different groups to ensure a fair comparison between the new treatment and the placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo, to prevent bias in the results. The trial will continue for a set period, during which the safety and effectiveness of the treatment will be closely monitored.

1 randomization

Upon joining the study, participants are randomly assigned to one of two groups. One group receives the medication axatilimab along with corticosteroids, while the other group receives a placebo with corticosteroids. This process is double-blind, meaning neither the participants nor the researchers know who is receiving which treatment.

2 initial treatment phase

Participants begin the initial treatment phase. Those in the axatilimab group receive the medication either through an intravenous (IV) or subcutaneous (SC) route. The corticosteroids, such as prednisone or methylprednisolone, are administered orally or intravenously, depending on the specific medication and dosage required.

The dosage and frequency of administration are determined by the study protocol and the participant’s specific needs.

3 monitoring and assessment

Throughout the study, participants undergo regular monitoring to assess the effectiveness of the treatment. This includes evaluating the response to the medication and any side effects experienced.

The primary goal is to determine the time from the start of the study to the occurrence of any significant events, such as the need for additional therapy, treatment failure, or any other adverse outcomes.

4 response evaluation

At six months, participants’ responses to the treatment are evaluated. This involves assessing whether there has been a complete or partial response to the treatment without the need for new systemic therapy.

The evaluation is based on established criteria for chronic graft-versus-host disease, focusing on improvements in symptoms and overall health.

5 follow-up

Participants continue to be monitored for any long-term effects of the treatment. This includes regular check-ups and assessments to ensure the ongoing health and safety of the participants.

The study is expected to continue until March 2030, with participants being followed up throughout this period to gather comprehensive data on the treatment’s effectiveness and safety.

Who Can Join the Study?

Must be at least 12 years old at the time of giving consent to participate in the study.
Must be able to understand and willing to sign a written consent form. If the participant is a child, a parent or guardian must provide consent, and the child should also sign an assent form if possible.
Must have a new case of moderate or severe chronic graft-versus-host disease (cGVHD), which is a condition that can occur after a bone marrow or stem cell transplant. This condition requires treatment that affects the whole body. Moderate cGVHD involves at least one organ with a certain level of severity, or multiple organs with milder involvement. Severe cGVHD involves at least one organ with a high level of severity.
Must have a history of receiving an allogeneic hematopoietic cell transplant (allo-HCT), which is a type of transplant using cells from a donor. The donor can be related or unrelated, and the cells can come from bone marrow, blood, or umbilical cord blood.
Must have a Karnofsky Performance Status (KPS) score of 60% or higher if 16 years or older, or a Lansky Performance Status (LPS) score of 60% or higher if younger than 16. These scores measure the ability to perform daily activities.
Must have adequate blood cell levels, specifically an absolute neutrophil count (ANC) of at least 0.5 x 10⁹/L without the help of growth factors for at least 7 days before joining the study. Neutrophils are a type of white blood cell important for fighting infections.
Must agree to avoid pregnancy or fathering children during the study and for a period after the study. Men must take precautions to avoid fathering children and not donate sperm. Women who can become pregnant must have negative pregnancy tests and agree to use effective birth control methods. Women who cannot become pregnant are also eligible.

Who Cannot Join the Study?

Patients who have a different condition than chronic graft-versus-host disease cannot participate. This is a condition that can occur after a transplant, where the donated cells attack the patient’s body.
Patients who are not in the age range specified for the study cannot participate. The study includes certain age groups, so if you are outside these groups, you cannot join.
Patients who are not willing or able to follow the study procedures cannot participate. This means you need to be able to attend appointments and follow instructions given by the study team.
Patients who are pregnant or breastfeeding cannot participate. This is to ensure the safety of both the mother and the baby.
Patients who have another medical condition that might interfere with the study cannot participate. This is to make sure the study results are accurate and not affected by other health issues.
Patients who are taking certain medications that might interfere with the study cannot participate. Some medications can affect how the study treatment works.
Patients who have participated in another clinical trial recently cannot participate. This is to avoid any interference from other treatments or medications.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Medical University Of Vienna	Vienna	Austria
Center For Pediatric And Adolescent Medicine Of The Johannes Gutenberg University Mainz	Mainz	Germany
Hospital Universitario De Salamanca	Salamanca	Spain
Medical University Of Graz	Graz	Austria
Medizinische Universitaet Innsbruck	Innsbruck	Austria
Oncopole Claudius Regaud	Toulouse	France
Technische Universitaet Dresden	Dresden	Germany
Hospital Universitario Y Politecnico La Fe	Valencia	Spain

Other Sites

Site Name	City	Country
Ospedale San Raffaele S.r.l.	Milan	Italy
Rheinische Friedrich-Wilhelms-Universitaet Bonn	Bonn	Germany
Centre Hospitalier Universitaire De Nantes	Nantes	France
Centre Hospitalier Universitaire De Nice	Nice	France
Hospital General Universitario Gregorio Maranon	Madrid	Spain
Universitätsklinikum des Saarlandes – Homburg/Saar, Klinik für Urologie und Kinderurologie	Homburg	Germany
Azienda Universitaria Ospedaliera Consorziale Policlinico Bari	Bari	Italy
Idcnvhyg Plhmtjknuppzird Cshlny Cbqjpp	Marseille	France
Hujgexde Veau djqsmeck	Barcelona	Spain
Vjzcxx dfa Rvooi Uezjgkytjy Hcebkgjq	Sevilla	Spain
Uejprjhmnzcavsagekbpb Efkrhkss Aim	Erlangen	Germany
Atuv Gxxqqf Oemckyfs Mvteabnqvyrwz Njhpvidc	Milan	Italy
Fygrqojtwn Isclj Pdfywbbhlmz Sqf Mfxddl	Pavia	Italy
Aftvthflt Uxa	Amsterdam	The Netherlands
Ckltjzr Uxbyqbgpjillljpbyvfz Bypict Kqc	Berlin	Germany
Ugupffcxttzlhpghkylej Dbidhtjyubz Any	Duesseldorf	Germany
Pizuinngbzirukzminxbw Mqogugy	Marburg	Germany
Ikwmr Ondfbkoq Pfjkrzjmkwn Scn Mngvzsy	Genoa	Italy
Utfzrwyutgnedbutd Pyinhwhrjtk Drrxc Mcygns	Ancona	Italy
Ujbiuxevbukeoiexztfdg Mcgrmglr Afj	Munster	Germany
Ajvjvhe Okracaoorik Uuwolwbvwnqpb Ftamobsj Ih Dg Nxagxq	Naples	Italy
Cyku Dj Nxdrg	Vandoeuvre Les Nancy	France
Uirfexjofxgpxibudaagd Wsixdngqf Ajj	Wuerzburg	Germany
Cpxjuj Htcbijypqlo Uudqyguqfrvwr Apwbql Pohkiwsr	Amiens	France
Urahkekzuk Hcwzcygj Mffsfqazpd	Maastricht	The Netherlands
Ugtiurpwfakg Linpspp	Leipzig	Germany
Rbuckqowlhllxz	Copenhagen	Denmark
Axhsoya Uachb Staehogey Lbunuf Dl Bpvzfeo	Bologna	Italy
Hvxkapkm Dq Lg Swejk Cjna I Sdjv Pzy	Barcelona	Spain
Aupumsq Ohgychvevbn Pojm Gpnmfvwu Xhszn	Bergamo	Italy
Uoduvyrpqjziydlhhmiad Eqvhm Aef	Essen	Germany
Urinafqmif Dfzwa Shbyu Dj Rgnc Lg Stzkufac	Rome	Italy
Oonggyakicccgu Lenp Gtuv	Linz	Austria
Ixbojlro fgxf Kdxibmdne Tzskapurhumjhgbsdzh ucf Igadxusqgwyu Upd goium	Ulm	Germany
Uhqediszbkhkcypydgpkl Axbrrm Aax	Aachen	Germany
Ujjymofayfcxemngftoln Sagucoeqkapqndnrye Amz	Kiel	Germany
Son Ahqo Ktsdicqqcvjs Gfhz	Vienna	Austria
Cabdmw Hbcfmtyxwbj Lstg Scf	Pierre Benite	France
Hslgpwmj Ukubyanohmckv Poduqc Dg Hqzgcg Df Mhdgfngwnya	Majadahonda	Spain
Igndnqbn Ckbxlv Djpdqtvhzyirroirp	L'hospitalet De Llobregat	Spain
Upmerntxci Dmxgt Srgqg Dm Bsotyzp	Brescia	Italy
Ojbwxiaz Perpzhmuvg Buwddmq Gkrrvalhpsy	Rome	Italy
Htjnkxg Sdzvl Amremru	Paris	France
Afyafqq Oojwywargraosonkdhllekpjc Pwgheywhjtr Gu Rkcfslayiiab Mwwzd Dm Cerozvz	Catania	Italy
Gkstpp Ocbbegjm Myiqlaiuwfhve Bxrbmba Mzograhkv Mtmjlmw	Reggio Calabria	Italy
Pqk Fjbpplcvak Do Chbzv E Rzboxmvbl Cvcg G Psclyj	Tricase	Italy
Alfixts Ohkalpkwflj Odnksqkg Rodqjep Voeeh Suhog Cxynzprj	Palermo	Italy
Abnnezxwcy Pbcreaqg Hinnsknv Db Pjgmm	Paris	France
Hwbizdcn Utxmmbhksmaul Dyrqprhf	Donostia / San Sebastian	Spain
Aszrius Odgfnedqzyv Ndufsivlq Sq Amjxsfn E Btfjas E C Aipklu Azlnwqdmnfm	Alexandria	Italy
Cwkurq Rqqskubr Cfbryecj Dr Vxdfro Sfmfrl	Verona	Italy
Cfpm Szjyxdfz Dxhxw Soemjnwxjr	San Giovanni Rotondo	Italy
Mrytxmmdjzcryxsaoealuomgid Hrspqsgipnppuadv	Halle (Saale)	Germany
Ez Hcnvrgpt Usqeykbcapbvp Dx Gbxh Ccfhxfb Dyx Nnggrm	Las Palmas De Gran Canaria	Spain

Trial status

Country	Status	Recruitment Start
Austria	Recruiting	01.01.2025
Denmark	Recruiting	01.01.2025
France	Recruiting	01.01.2025
Germany	Recruiting	01.01.2025
Ireland	Recruiting	01.01.2025
Italy	Recruiting	01.01.2025
Spain	Recruiting	01.01.2025
The Netherlands	Recruiting	01.01.2025

Trial locations

Investigated Drugs:

Axatilimab: This is an investigational medication being studied for its potential to help treat chronic graft-versus-host disease (cGVHD). It is being tested to see if it can improve symptoms when used alongside corticosteroids.

Corticosteroids: These are a type of medication commonly used to reduce inflammation and suppress the immune system. In this trial, they are used in combination with axatilimab to treat chronic graft-versus-host disease.

Chronic Graft-Versus-Host Disease – This condition occurs when donor cells attack the recipient’s body after a stem cell or bone marrow transplant. It can affect various organs, including the skin, liver, and digestive tract. Symptoms may include skin rashes, dry eyes, and mouth, as well as joint pain. The disease can develop months or even years after the transplant. It often progresses slowly, with periods of worsening and improvement. The severity and specific symptoms can vary widely among individuals.

Trial ID:

2023-510292-65-00

Protocol code:

INCA34176-357

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Axatilimab and Corticosteroids for Initial Treatment of Chronic Graft-Versus-Host Disease in Patients

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?